全文获取类型
收费全文 | 370篇 |
免费 | 16篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 46篇 |
口腔科学 | 2篇 |
临床医学 | 15篇 |
内科学 | 85篇 |
皮肤病学 | 5篇 |
神经病学 | 19篇 |
特种医学 | 12篇 |
外科学 | 84篇 |
综合类 | 1篇 |
预防医学 | 20篇 |
药学 | 59篇 |
中国医学 | 3篇 |
肿瘤学 | 31篇 |
出版年
2022年 | 2篇 |
2021年 | 4篇 |
2020年 | 5篇 |
2019年 | 3篇 |
2018年 | 5篇 |
2017年 | 4篇 |
2016年 | 11篇 |
2015年 | 8篇 |
2014年 | 6篇 |
2013年 | 11篇 |
2012年 | 12篇 |
2011年 | 22篇 |
2010年 | 15篇 |
2009年 | 14篇 |
2008年 | 18篇 |
2007年 | 28篇 |
2006年 | 23篇 |
2005年 | 31篇 |
2004年 | 13篇 |
2003年 | 16篇 |
2002年 | 8篇 |
2001年 | 15篇 |
2000年 | 8篇 |
1999年 | 10篇 |
1998年 | 4篇 |
1997年 | 5篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1992年 | 11篇 |
1991年 | 7篇 |
1990年 | 7篇 |
1989年 | 7篇 |
1988年 | 5篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1977年 | 4篇 |
1975年 | 3篇 |
1974年 | 1篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1971年 | 3篇 |
1970年 | 3篇 |
1969年 | 1篇 |
1968年 | 2篇 |
1967年 | 5篇 |
1966年 | 1篇 |
1965年 | 4篇 |
排序方式: 共有388条查询结果,搜索用时 15 毫秒
131.
A study of ten Japanese patients with seronegative spondylarthropathy: a tentative proposal 总被引:2,自引:0,他引:2
Higashi S Nakamura T Tomoda K Tsukano M Sakaguchi M Kuga F 《Modern rheumatology / the Japan Rheumatism Association》2005,15(5):329-335
We reviewed ten patients with seronegative spondylarthropathy (SNSA), who all fulfilled the European Spondylarthropathy Study Group criteria for spondylarthropathy (SpA); seven patients also met the Amor criteria for SpA. Seronegative spondylarthropathy was not a uniform syndrome but rather a wide spectrum of complex disease with characteristics of sacroiliitis and enthesopathy. The most frequent symptom at diagnosis of SNSA was inflammatory low back pain, followed by asymmetric oligoarthralgia and Achilles tendonitis and/or plantar fasciitis. Systemic complications were revealed as eye and skin involvement. Imaging methods including pelvic radiography, scintigraphy, and computed tomography scanning were useful in detecting spondylarthropathic changes, which were characteristic of SNSA. Human leukocyte antigen (HLA) typing showed various patterns among patients, in which HLA-B27 was positive in three patients with ankylosing spondylitis. HLA-B51, which is a well-known genetic factor associated with Behçet's disease (BD), was positive in two patients who were apparently distinct from BD. Two patients with palmoplantar pustulosis showed symptoms and signs characteristic of SNSA. Although we have few SNSA patients in the present study, we would like to propose that HLA-B51 positive SpA would be considered as a subset of SNSA, and that pustulotic SpA also would be classified as a member of SNSA. This led us to suggest the possibility to change the concept of SNSA proposed by Moll et al. The optimal treatment remains to be defined, but sulfasalazine was effectively used with almost all patients in combination with nonsteroidal anti-inflammatory drugs. 相似文献
132.
Narimatsu H Kami M Hara S Matsumura T Miyakoshi S Kusumi E Kakugawa Y Kishi Y Murashige N Yuji K Masuoka K Yoneyama A Wake A Morinaga S Kanda Y Taniguchi S 《Bone marrow transplantation》2005,36(6):517-523
Thrombotic microangiopathy (TMA) is a significant complication after hematopoietic stem-cell transplantation (HSCT); however, there is little information on it following reduced-intensity cord blood transplantation (RI-CBT). We reviewed the medical records of 123 adult patients who received RI-CBT at Toranomon Hospital between January 2002 and August 2004. TMA was diagnosed in seven patients based on intestinal biopsy (n = 6) or autopsy results (n = 1). While these patients showed some clinical symptoms such as diarrhea and/or abdominal pain, mental status alterations or neurological disorders were not observed in any of them. Laboratory results were mostly normal at the onset of TMA; >2% fragmented erythrocytes (n = 1), <10 mg/dl haptoglobin (n = 1), and >200 IU/dl lactic dehydrogenase (LD) (n = 4). On endoscopic examination, TMA lesions, consisting of ulcers, erosions, and diffuse exfoliation, were distributed spottily from terminal ileum to rectum. Intestinal graft-versus-host disease (GVHD) and cytomegalovirus (CMV) colitis were confirmed in five and four patients, respectively. With therapeutic measures including supportive care (n = 4), fresh frozen plasma (n = 1), and a reduction of immunosuppressive agents (n = 1), TMA improved in four patients. The present study demonstrates that intestinal TMA is a significant complication after RI-CBT. Since conventional diagnostic criteria can overlook TMA, its diagnosis requires careful examination of the gastrointestinal tract using endoscopy with biopsy. 相似文献
133.
134.
135.
K Kaito K Nishiwaki H Masuoka T Shimada M Yoshida S Ochiai T Katayama M Kobayashi A Saito R Watanabe 《[Rinshō ketsueki] The Japanese journal of clinical hematology》1992,33(6):776-782
The authors evaluated the efficacy of a daily administration of recombinant human alpha 2a interferon (IFN), given at a dose of 300MU for 12 consecutive days, in patients with steroid-nonresponsive or -dependent idiopathic thrombocytopenic purpura (ITP). Nine patients received courses of IFN therapy. Mean platelet counts rose from 1.39 to 10.9 x 10(4)/microliters and PAIgG decreased from 151.7 to 59.7 ng/10(7) cells. The maximum rise in platelet counts occurred from 10 to 42 days (mean 19.1) after the initiation of IFN. Complete response (CR) was achieved in 3 of 13 courses (23.1%), and partial response (PR) in 8 (61.5%). One CR case continued for longer than 20 months without further treatment, but intermittent IFN therapy was necessary for the other. The increment of the platelet counts was transient in all of the partial responders. No severe side effect requiring interruption of the course of IFN was experienced. Both serum IgG and PAIgG significantly correlated with the increment of platelet counts, therefore the mechanism of IFN on ITP was presumed to be associated with the inhibition of autoantibody production. Daily administration of IFN appears to be an effective and safe treatment protocol for refractory ITP. 相似文献
136.
David T. Masuoka Alejando F. Alcaraz Hermann F. Schott 《Biochemical pharmacology》1982,31(11):1969-1974
The injection of reserpine, 5 mg/kg i.p. (ipRes), the regimen employed by a majority of investigators, results in synaptosomal and vesicular preparations which are incompletely reserpinized as determined by [3H]dopamine ([3H]DA) accumulation. Reserpine administered by the subcutaneous route, 5 mg/kg (scRes), appears to produce complete reserpinization. Release of [3H]DA by d-amphetamine (Amph) was observed from striatal synaptosomes prepared both from normal rats and those pretreated with reserpine intraperitoneally but not from those injected subcutaneously. In the more completely reserpinized scRes synaptosomes, so little [3H]DA had accumulated that release by Amph was not measurable, indicating that if a labile, reserpine-resistant, extravesicular DA storage pool releasable by Amph is present under these conditions, it must be extremely small. In scRes monoamine oxidase (MAO)-inhibited preparations, Amph released preloaded [3H]DA located in the cytosol in the absence of functional vesicles. Although Chromatographic analysis of the superfusate from ipRes striatal synaptosomes showed that significant amounts of preloaded [3H]DA were released by Amph, the level of dihydroxyphenylacetic acid was not increased over controls, indicating that Amph releases only DA and not its metabolite and is also acting as a MAO inhibitor. No [3H]DA could be released by Amph from superfused hyposmotically shocked normal or ipRes synaptosomes, suggesting that an intact membrane is required for Amph-induced release. 相似文献
137.
Yuji Yasunobu Kozo Hayashi Tetsuji Shingu Katsuhiko Nomura Yoshifumi Ohkura Kouichi Tanaka Yoshio Kuga Syu-ichi Nomura Harumi Ohtani Takaharu Nishimura Hideo Matsuura Goro Kajiyama 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》1997,11(4):567-574
The effects of cerivastatin sodium (BAY w 6228), a new type of inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase, on plasma cholesterol concentrations and the induction of hepatic LDL receptors were investigated with beagle dogs
and Hep G2 cells. Oral administration of cerivastatin (0.01, 0.03, and 0.1 mg/kg per day) for 3 weeks reduced plasma total
and very low-density lipoprotein plus low-density lipoprotein (VLDL + LDL) cholesterol concentrations and increased hepatic
LDL receptor binding activity in dogs. Scatchard plot analysis revealed a 1.9-fold increase in the maximum binding capacity
of hepatic LDL receptors in cerivastatin-treated animals. Similar results were obtained by administration of pravastatin (1.0
and 5.0 mg/kg/day) for 3 weeks. Binding activity of the LDL receptor, as well as receptor mRNA and protein concentrations,
were increased in a dose-dependent manner (0.01–1.0 μM) by exposure of Hep G2 cells to cerivastatin. The results suggest that
cerivastatin reduces plasma cholesterol concentrations by increasing hepatic LDL receptor expression. The mechanism of lowering
cholesterol concentration by cerivastatin was the same as with the other previously examined HMG-CoA reductase inhibitors,
but the effects with cerivastatin were apparent at doses much lower than the effective doses of the other drugs. Cerivastatin,
therefore, shows potential for clinical use as a potent and efficacious plasma cholesterol-lowering drug.
This revised version was published online in July 2006 with corrections to the Cover Date. 相似文献
138.
139.
Right‐sided aortic arch and aberrant left subclavian artery with or without a left nonrecurrent inferior laryngeal nerve 下载免费PDF全文
Hiroo Masuoka MD PhD Akira Miyauchi MD PhD Takuya Higashiyama MD PhD Tomonori Yabuta MD PhD Minoru Kihara MD PhD Akihiro Miya MD PhD 《Head & neck》2016,38(10):E2508-E2511
140.